Myocardial injury and coagulopathy in COVID-19: A boon or a bane when using anticoagulation

Myocardial injury and coagulopathy in COVID-19: A boon or a bane when using anticoagulation

Myocardial injury and coagulopathy in COVID-19: A boon or a bane when using anticoagulation

Infectious DiseasesCardiologyFamily MedicineGeneral PracticeHaematology
A badge with ribbon in color black Point(s): 1 | An analog clock in color black 1 hour | A black calendar with white triangle in center that has a black exclamation point in the middle 21 Jan 2023 

Overview

About this course

Angiotensin-converting enzyme 2 (ACE2) is an enzyme that conveys protective effects on the cardiovascular system. However, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) spike protein binds to ACE2 receptors in the cells enabling entry of the virus into human tissues. The presence of ACE2 receptors in the myocardium leads to myocardial injury through different mechanisms and produces varied cardiac manifestations. Likewise, hyperinflammation in COVID-19 leads to thrombotic events making coagulopathy one of the leading causes of death in severe COVID-19 disease. This e-learning module summarizes the myocardial injury caused by SARS-CoV-2, coagulopathy, and the use of anticoagulants in the management of COVID-19 disease.


Learning outcomes

Upon completion of the educational activity, health care providers should be able to:
  • Understand the mechanism of cardiac injury and coagulopathy caused by SARS-CoV-2
  • Evaluate the use of anticoagulants in COVID-19 infection

Topics covered

  • COVID-19 myocardial injury and coagulopathy
  • Anticoagulation in COVID-19 infection

1 CPD Point Available